Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain

References

• World Health Organization. Cancer pain relief and palliative care: report of a WHO expert committee, 2nd ed. Geneva: World Health Organization Technical Report Series; 1996
   Google Scholar
• Watson CP, Watt-Watson JH, Chipman ML. Chronic noncancer pain and the long-term utility of opioids. Pain Res Manag 2004;9:19–24
   PubMedGoogle Scholar
• Portenoy RK. Progress in pain research and management; pharmacological approaches in the treatment of chronic pain: new concepts and critical issues. Opioid therapy for chronic nonmalignant pain: current status. Seattle, WA: IASP Press; 1994
   Google Scholar
• Schug S, Merry A, Acland R. Treatment principles for the use of opioids in pain of non-malignant origins. Drugs 1991;42:228–39
   Google Scholar
• Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000;14:111–9
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997;13:254–61
   PubMed Web of Science ®Google Scholar
• Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527–34
   PubMed Web of Science ®Google Scholar
• Zech DFJ, Grond SUA, Lynch J, et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992;50:293–301
   Google Scholar
• Cherny NI, Coyle N, Foley KM. Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 1994;10:57–70
   Google Scholar
• Lorusso P, Davies C, Vergidis D. Use of sustained-release strong opioids after weak opioids. In: Devor M, Rowbotham MC, Wiesenfeld-Hallin Z, editors. Proceedings of the ninth world congress on pain. Seattle: IASP Press, 2001 [ISBN 0–931092–31–0]
   Google Scholar
• van Seventer R, Smit JM, Schipper RM, et al. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19(6):457–69
   PubMed Web of Science ®Google Scholar
• Johnson M, Mortimer S, Bogle S, Hallam SJ. A study to compare subject acceptability of DuragesicTM with sustained release morphine in subjects requiring strong opioids for chronic non-malignant pain. Http://www.janssen-cilag.com/content/backgrounders/janssen-cilag.com/SynopsisFEN-GBR-21.pdf
   Google Scholar
• Allan L, Kalso E. Randomized trial of transdermal fentanyl and sustained release oral morphine in persistent low back pain. In: Pain in Europe IV – 4th congress of the European Federation of IASP Chapters (EFIC), Prague, Czech Republic, September 2–6, 2003. p. 260
   Google Scholar
• Tawfik MO, Bryuzgin V, Kourteva G on behalf of the FEN-INT-20 study group. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 2004;20(3):259–67
   Google Scholar
• Dizdar Y, Kucucuk S, Kaytan E, et al. Evaluation of the clinical efficacy of transdermal fentanyl (Durogesic®) in adults with cancer-related pain: an open multicentre study, on behalf of Durogesic Mewa Working group. In: Pain in Europe IV – 4th congress of the European Federation of IASP Chapters (EFIC), Prague, Czech Republic, September 2–6, 2003. p. 300. http://www.janssen-cilag.com/content/backgrounders/janssencilag.com/LMD.pdf; http://www.janssen-cilag.com/content/backgrounders/janssen-cilag.com/LMD2.pdf
   Google Scholar
• Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001;2(4):197–204
   PubMed Web of Science ®Google Scholar
• Bjorneboe O, Pavelka K. Effects of transdermal fentanyl on pain and functioning in rheumatoid arthritis. In: Pain in Europe IV – 4th congress of the European Federation of IASP Chapters (EFIC), Prague, Czech Republic, September 2–6, 2003. p. 249
   Google Scholar
• Herrero-Beaumont G, Le Loet X. Effects of transdermal fentanyl on pain and functioning in osteoarthritis. In: Pain in Europe IV – 4th congress of the European Federation of IASP Chapters (EFIC), Prague, Czech Republic, September 2–6, 2003. p. 250
   Google Scholar
• Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322:1154–8
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Befon S, Kouskouni E, et al. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 2001;21:2225–30
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Parpa E, Tsilika E, et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 2003;4:298–306
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Befon S, Tsilika E, et al. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology 2002;62:9–16
   PubMed Web of Science ®Google Scholar
• Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 2003;26:1026–48
   Google Scholar
• Wiffen PJ, Edwards JE, Barden J, McQuay HJM. Oral morphine for cancer pain. Cochrane Review. In: The Cochrane library, issue 2. Chichester (UK): John Wiley and Sons, Ltd; 2004
   Google Scholar
• Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs 1995;6(Suppl 3):39–43
   PubMedGoogle Scholar
• Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs 1995;6 (Suppl 3):29–34
   PubMed Web of Science ®Google Scholar
• Korte W. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996;11:139–46
   PubMed Web of Science ®Google Scholar
• Mercadante S, Fulfaro F. Alternatives to oral opioids for cancer pain. Oncology 1999;13:215–25
   PubMed Web of Science ®Google Scholar
• Nugent M, Davis C, Brooks D, Ahmedzai SH. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage 2001;21:385–91
   PubMed Web of Science ®Google Scholar
• Megens AAHP, Artois K, Vermeire J, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998;15:253–8
   PubMed Web of Science ®Google Scholar
• Yeo W, Lam KK, Chan AT, et al. Transdermal fentanyl for severe cancer-related pain. Palliat Med 1997;11:233–9
   PubMed Web of Science ®Google Scholar
• Grond S, Zech D, Lehmann KA, et al. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997;69:191–8
   PubMed Web of Science ®Google Scholar
• Menten J, Desmedt M, Lossignol D, et al. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 2003;18:488–98
   Web of Science ®Google Scholar
• Sabatowski R, Schwalen S, Rettig K, et al. Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage 2003;25:38–47
   PubMed Web of Science ®Google Scholar
• Weiss SC, Emanuel LL, Faiclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet 2001;357:1311–5
   PubMed Web of Science ®Google Scholar